As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Moderna has gotten torched over the last six months - since September 2024, its stock price has dropped 51.2% to $33.99 per ...

The "mRNA Cancer Therapeutics Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. The mRNA cancer therapeutics market was valued at USD 13.23 ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Today, we are looking at therapeutics stocks, starting with Myriad Genetics (NASDAQ:MYGN). Moderna (NasdaqGS:MRNA) recently faced significant legal challenges with five international lawsuits from ...

Arcturus Therapeutics believes it’s “highly unlikely” it will lose the promised government funding for its bird flu mRNA ...

Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with ...

Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. Just who are these companies and who is behind them, asks ...

Hantson had taken the opportunity to cut a swathe through its R&D programme, including three research partnerships: collaborations with Moderna Therapeutics, Blueprint Medicines and Arbutus ...

Moderna is a biotechnology company primarily ... It spearheads innovation using mRNA technology to pursue vaccines and therapeutics for a range of diseases, including COVID-19, cancer, and rare ...

Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: ...